On Wednesday, B.Riley adjusted its price target for PDS Biotechnology Corp (NASDAQ:PDSB), a company specializing in immunotherapies for cancer, from $11.00 to $9.00, while maintaining a Buy rating on the stock. This revision follows a comprehensive review of the competitive landscape in immunotherapy treatments for HPV-positive head and neck cancers, as well as an update to the company's earnings model post first-quarter results.
The updated price target reflects a strategic shift by PDS Biotechnology towards a development strategy that emphasizes a triplet regimen combining its tumor-activated IL-12 ADC with PDS0101 or Versamune HPV and Keytruda. This decision was influenced by recent data presented at a session focused on novel therapeutics for head and neck squamous cell carcinoma (HNSCC) that took place on June 4. The session highlighted three key abstracts from competitors that are also focusing on HPV-positive patients through different immunotherapy approaches.
The firm noted that Merck's Keytruda, both as a monotherapy and in combination with chemotherapy, showed limited efficacy in a subset of HPV-positive HNSCC patients with low PDL1 expression. In contrast, impressive results were reported from a Phase I/II study of petosemtamab, an EGFR/LGR5 targeted bispecific antibody, which showed a 67% objective response rate in a cohort treated in combination with Keytruda, regardless of HPV status.
B.Riley expressed optimism about PDS Biotechnology's registration strategy, particularly the potential for its triplet regimen to replicate the success seen with petosemtamab in the first-line treatment of HPV-positive HNSCC patients. The analyst sees PDS Biotechnology's approach as potentially offering a comparable or superior alternative to existing treatments. The company's focus on developing a treatment regimen that targets the HPV-positive patient population in the first-line setting is a key aspect of its strategy moving forward.
In other recent news, PDS Biotechnology Corporation announced the appointment of Stephan Toutain as Chief Operating Officer. Toutain, with his extensive experience in the pharmaceutical industry, will contribute to the company's strategic vision and operational excellence as they prepare to initiate a pivotal clinical trial for advanced head and neck squamous cell cancers with their lead program in 2024.
In parallel, B.Riley adjusted the price target for PDS Biotechnology's shares to $11.00, a decrease from the previous $14.00, while retaining a Buy rating. The adjustment is in anticipation of further data from ongoing clinical trials, including the VERSATILE-002 study and two investigator-sponsored trials.
Furthermore, PDS Biotech reported a net loss of $42.9 million for the year-end 2023 during their earnings call. Despite the loss, the company confirmed a cash balance that should support operations into Q4 2025. The company also detailed progress in their PDS0101 Phase 2 programs and expressed a decision to focus on the triple combination therapy for recurrent and metastatic head and neck cancer.
InvestingPro Insights
Amidst the strategic developments at PDS Biotechnology Corp (NASDAQ:PDSB), investors are closely monitoring the company's financial health and stock performance. A key highlight from InvestingPro shows that PDS Biotechnology holds more cash than debt on its balance sheet, a reassuring sign of financial stability. Furthermore, two analysts have recently revised their earnings upwards for the upcoming period, suggesting a growing confidence in the company's prospects. This optimism is tempered by the recognition that the stock has experienced significant volatility, as evidenced by its recent price declines, including a drop of over 8% in the last week alone.
From a financial standpoint, PDS Biotechnology's market capitalization stands at $101.23 million, with a negative P/E ratio of -2.05 indicating that the company is not currently profitable. Additionally, PDS Biotechnology's stock is trading near its 52-week low, which could present a potential entry point for investors who believe in the company's long-term strategy and are comfortable with high volatility.
For those looking to delve deeper into PDS Biotechnology's financials and stock performance, InvestingPro offers additional insights and tips. There are 12 additional InvestingPro Tips available for PDS Biotechnology, which can be accessed by visiting https://www.investing.com/pro/PDSB. Investors interested in leveraging these insights can use the promo code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.